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Abstract
Background: B. burgdorferi sensu lato (sl) is the etiological agent of Lyme borreliosis in humans. Spirochetes have
adapted themselves to the human immune system in many distinct ways. One important immune escape
mechanism for evading complement activation is the binding of complement regulators Factor H (CFH) or Factor
H-like protein1 (FHL-1) to Complement Regulator-Acquiring Surface Proteins (CRASPs).
Results: We demonstrate that B. garinii OspA serotype 4 (ST4) PBi resist complement-mediated killing by binding
of FHL-1. To identify the primary ligands of FHL-1 four CspA orthologs from B. garinii ST4 PBi were cloned and
tested for binding to human CFH and FHL-1. Orthologs BGA66 and BGA71 were found to be able to bind both
complement regulators but with different intensities. In addition, all CspA orthologs were tested for binding to
mammalian and avian CFH. Distinct orthologs were able to bind to CFH of different animal origins.
Conclusions: B. garinii ST4 PBi is able to evade complement killing and it can bind FHL-1 to membrane expressed
proteins. Recombinant proteins BGA66 can bind FHL-1 and human CFH, while BGA71 can bind only FHL-1. All
recombinant CspA orthologs from B. garinii ST4 PBi can bind CFH from different animal origins. This partly explains
the wide variety of animals that can be infected by B. garinii.
Background
Borrelia burgdorferi sensu lato (sl), the etiologic agent of
Lyme borreliosis, is a genetically diverse species. The
different genospecies of B. burgdorferi sl appear to be
associated with different manifestations of the disease
[1,2]. B. burgdorferi sensu stricto (ss) is more common
in North America but also found in Eurasia and is asso-
ciated with arthritis, while B. garinii and B. afzelii are
only present in Eurasia and are more commonly asso-
ciated with Lyme neuroborreliosis and cutaneous mani-
festations, respectively. Specifically B. garinii OspA
serotype 4 (ST4) strains, a genetically homogenous
group, are frequently observed as a causative agent of
neuroborreliosis in adults in Europe [3-6]. Recently it
has also been proposed, though not yet generally
accepted, to delineate the B. garinii ST4 strains as a
separate species, B. bavariensis, due to large differences
compared to B. garinii non-ST4 in multilocus sequence
analysis (MLSA) on several housekeeping genes [7].
The different human pathogenic genospecies are asso-
ciated with certain human serum resistance profiles; the
majority of B. burgdorferi ss and B. afzelii strains are
relatively resistant to human serum, while most B. gari-
nii strains are highly sensitive to complement-mediated
killing in vitro. Among B. garinii,t h eS T 4s t r a i n s
showed a similar resistant profile as B. burgdorferi ss
and B. afzelii [8-10].
B. burgdorferi sl has developed a variety of immune
evasion strategies, among which the binding of two
host-derived fluid-phase regulators of complement:
Factor H (CFH) and Factor H-like protein 1 (FHL-1).
CFH and FHL-1 the main immune regulators of the
alternative pathway of complement activation, are
structurally related proteins composed of several pro-
tein domains termed short consensus repeats (SCRs)
[11]. CFH is a 150-kDa glycoprotein composed of 20
SCR domains. In contrast, FHL-1 is a 42-kDa glyco-
protein corresponding to a product of an alternatively
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SCRs. The seven N-terminally located SCRs of both
complement regulators are identical with the exception
of four additional amino acids at the C-terminus of
FHL-1 [12]. CFH and FHL-1 in the human host are
responsible for preventing binding of factor B to C3b,
supporting the dissociation of the C3bBb complex and
acting as a cofactor for factor I-mediated cleavage of
C3b, the central component of the three complement
activation pathways [12-15].
Serum resistant Borrelia acquire CFH and/or FHL-1
by direct interaction with outer surface proteins desig-
nated CRASPs (Complement Regulator-Acquiring Sur-
face Proteins) [16]. Previously, five different CRASPs
have been described for B. burgdorferi ss and B. afzelii.
The CFH and FHL-1 binding CspA protein is (also
designated CRASP-1) encoded by cspA,ag e n el o c a t e d
on the lp54 plasmid. Although the lp54 plasmid of B.
burgdorferi and B. afzelii carries multiple genes encod-
ing a number of paralogous proteins, also called the
gbb54 orthologous family, only the CspA is capable of
binding human CFH and FHL-1 [17]. CspA is upregu-
lated by spirochetes during the tick-mammalian trans-
mission stage and down regulated during persistent
infection [18,19]. CspZ is a distinct protein encoded by
the cspZ gene located on plasmid lp28-3 and is
expressed at higher levels during the mammalian infec-
tion than in bacteria residing in ticks or during labora-
tory cultivation [18]. Anti-CspZ antibodies can be
detected as early as two weeks post infection in mice
infected by ticks [20]. CspZ has been shown to bind
other yet unknown proteins and therefore can have
multiple functions [19-22]. The CFH-binding CRASP
proteins BbCRASP-3, -4, and -5 belong to the OspE-
related proteins (Erp) paralogous family and their
respective genes are located on diverse cp32 prophage
DNA molecules [23]. Erp proteins are expressed in tis-
sues in the host during disseminated mammalian infec-
tion. Erp proteins have also been shown to be able to
bind to factor H related proteins-1 (CFHR1) and plasmi-
nogen [24-29].
In contrast to B. burgdorferi ss and B. afzelii most B.
garinii strains are unable to bind human complement
regulators [30]. Two CspA orthologs from B. garinii
ST6 ZQ1, named BgCRASP-1a and BgCRASP-1b,h a v e
been shown to bind weakly to FHL-1 but not to
human CFH [31]. Little data is published on comple-
ment evasion strategies of human serum resistant
strains of the B. garinii S T 4s t r a i n s .T h eg b b 5 4o r t h o -
logous family of B. garinii ST4 has not been studied
before.
It has been elaborately shown which gbb54 ortholog
from B. burgdorferi ss and B. afzelii can bind human
CFH, but little is known about the function of the other
orthologs. It has been described previously that CspA
derived from B. burgdorferi ss interacts with human
CFH; however none of the closely related protein of the
gbb54 family, interacts with human CFH [32]. Wallich
et al characterised all gbb54 orthologous members of a
B. afzelii and B. garinii strain wherein none of the
remaining orthologs couldb i n dh u m a nC F H / F H L - 1
[17,31]. We hypothesise that orthologs from the gbb54
family have the ability to bind to CFH from several ani-
mal origins.
The aim of the present study was to investigate the
mechanism for complement evasion by B. garinii ST4
strains and to isolate and functionally characterize the
specific gbb54 orthologs binding to human CFH/FHL-1
and also to other mammalian and avian CFH. We could
prove binding of 2 ST4 gbb orthologs, BGA66 and
BGA71, to human FHL-1, whereas BGA66 also bound
CFH. Moreover, both these and other orthologs from
the gbb54 family were also able to bind CFH from var-
ious animal species.
Results
Serum susceptibility testing of borrelial strains
To assess and to compare serum susceptibility of B. gar-
inii PBi and VSBP as well as B. burgdorferi ss B31, spir-
ochetes were incubated for 3 h with either 50% NHS or
50% HI NHS. As shown in Fig 1, >75% of the cells of B.
garinii ST4 PBi and B. burgdorferi ss B31 survived in
serum, indicating that both strains resist complement-
mediated killing. In contrast, B. garinii non-ST4 strain
VSBP was highly sensitive to complement as 99% of the
cells were immobilized and showed blebs after 3 hours.
Incubation of strains PBi, VSBP, and B31 with HI NHS
resulted in no or very little immobilisation. Summarising
B. garinii ST4 PBi and B. burgdorferi ss B31 are resistant
to human serum when incubated with active human
complement, while B. garinii non-ST4 VSBP is not
human serum resistant.
The detection of the membrane attack complex
deposited on borrelial cells after complement activation
To test whether membrane attack complex (MAC)
was formed on the surface of different strains after
complement activation, spirochetes were incubated
with 25% serum and deposition of the MAC was
detected by immuno-fluorescence microscopy (IF) (Fig
2). The majority of the cells of B. garinii ST4 PBi and
B. burgdorferi ss B31 stained negative for the MAC
while all B. garinii non-ST4 VSBP were fully covered
with MAC. This finding indicates that B. garinii ST4
PBi and B. burgdorferi ss B31 allow formation of the
MAC on their bacterial surface only to a limited
extent in comparison to B. garinii non-ST4 strain
VSBP.
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borrelial strains
In order to elucidate the capability of serum resistant B.
garinii ST4 PBi to bind complement regulators CFH
and FHL-1 to the surfaces in a non-denatured state,
intact spirochetes were incubated with NHS which was
supplemented with EDTA to prevent complement acti-
vation. Complement regulators were allowed to adsorb
to the Borrelia surface and bound proteins were subse-
quently eluted with acidified 0.1 M glycine. The wash
and the eluate fraction were analyzed for the presence
of CFH and FHL-1 by Western blotting. As shown in
Fig 3, FHL-1, but not CFH could be detected in the elu-
ate fraction indicating that B. garinii ST4 PBi specifically
interact with FHL-1.
Accessibility and surface exposure of CFH/FHL-1 binding
proteins of B. garinii ST4 PBi
In order to identify FHL-1 binding proteins produced by
B. garinii ST4 PBi and to determine whether these pro-
teins are exposed to the extracellular space, spirochetes
were treated with increasing concentrations of protei-
nase K or trypsin and proteolysis was detected by ligand
affinity blotting. Cell lysates obtained after protease
treatment were separated by SDS-PAGE, transferred to
nitrocellulose and the respective proteins were detected.
As shown in Fig 4, four distinct binding proteins could
be detected in untreated serum-resistant B. garinii ST4
PBi. Treatment with proteinase K at the lowest concen-
tration resulted in the complete elimination of CFH/
FHL-1 binding. Upon treatment with trypsin, degrada-
tion was only achieved at a concentration of 100 μg/μl.
As expected, the intracellular protein flagellin was resis-
tant to trypsin and proteinase K treatment, even at the
highest concentration. These data demonstrate that B.
garinii ST4 PBi produced up to four surface-exposed
CFH/FHL-1 binding proteins, in the range of 19-26
kDa. This is in concordance to the findings of McDo-
well et al, where B. garinii ST4 PBi expressed a 20.5 and
26 kDa protein that were found to interact with CFH
[33]. The CspA orthologs tested in this study are in the
range of 25-27 kDa, the smaller proteins detected
appear to belong to the Erp protein family.
Cloning and identification of the CFH/FHL-1 binding
proteins of B. garinii ST4 PBi
Assuming that the genes encoding CFH/FHL-1 binding
proteins of B. garinii ST4 PBi share similarity to CspA
encoding cspA gene of B. burgdorferi ss B31, B. afzelii
MMS and B. garinii ZQ1, a database search was con-
ducted. Four genes revealed a high degree of similarity
with either CspA of B. burgdorferi ss B31, B. afzelii
MMS or B. garinii ZQ1 as described previously [31,34].
BGA66, BGA67, BGA68 and BGA71 showed similarity
Figure 1 In vitro serum susceptibility of B. garinii ST4 PBi, B. garinii non-ST4 VSBP, and B. burgdorferi ss B31. Resistance to complement
was determined by counting motile spirochetes by dark-field microscopy and values obtained were represented as percentages of survival. All
strains were tested in triplicate with 50% NHS and HiNHS. VSBP is rapidly killed by complement, while >75%of B. burgdorferi ss B31 and B. garinii
ST4 PBi are alive after 3 hours of incubation.
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tive sequence analysis, revealed that orthologs BGA66
and BGA71 were found to have the highest degree of
similarity within the putative CFH/FHL-1 binding
regions of CspA (region 1-3)[35-37]. BGA66, BGA67,
BGA68 and BGA 71 as well as CspA of B. burgdorferi ss
strain B31 were cloned and expressed as GST fusion
proteins.
Determination of binding of CspA orthologs to CFH and
FHL-1
Binding of CFH and FHL-1 to non-denatured purified
recombinant proteins was evaluated by ligand affinity
blot. Proteins were separated under denaturing condi-
tions and subsequently blotted on a nitrocellulose mem-
brane. As shown in Fig 5, BbCspA used as positive
control bound strongly to CFH and FHL-1 as described
previously [34]. Orthologs BGA66 and BGA71 were cap-
able of binding to both complement regulators, however,
with reduced intensities compared to CspA.
To further confirm binding of CspA orthologs an
ELISA was conducted. CspA orthologs BGA66, BGA67,
BGA68, and BGA71 were immobilized on a microtiter
plate and binding of CFH and FHL-1 was evaluated (Fig
6). BbCRASP-1 used as a positive control strongly
bound to CFH and FHL-1. Of the four CspA orthologs
analyzed, BGA66 was capable of binding to both com-
plement regulators, this binding was significantly higher
than the baseline (p < 0.05). Ortholog BGA71 specifi-
cally bound to FHL-1 (p < 0.05) but less efficiently than
CspA and BGA66. In contrast, orthologs BGA67 and
BGA68 were not able to bind to CFH or FHL-1 at all.
These data confirmed that orthologs BGA66 as well as
BGA71 derived from B. garinii ST4 PBi were capable of
binding FHL-1. Binding of CFH in both assays is evident
for BGA66, but not for BGA71.
Figure 2 Detection of deposited C5b-9 complex on the surface of Borrelia by Immunofluorescence microscopy. B. garinii PBi and VSBP
and B. burgdorferi ss B31 were incubated with 25% NHS and deposition of C5b-C9 was detected by a MAb. Few cells of B. garinii ST4 PBi
stained positive for C5b-C9, while almost all spirochetes were covered with C5b-C9 using B. garinii non-ST4 VSBP. The absence of deposition of
C5b-C9 onto B. burgdorferi ss B31 is comparable to B. garinii ST4 PBi.
Figure 3 Detection of bound complement regulators by B.
garinii ST4 PBi. After incubation of spirochetes with NHS-EDTA,
bound proteins were eluted. The wash (w) and the eluate (e)
fraction were separated by SDS-PAGE. The last wash and eluate
fraction were subjected to SDS-PAGE and separated proteins were
blotted on nitrocellulose. CFH and FHL-1 were visualised using a
polyclonal goat anti-factor CFH antiserum (Calbiochem). It is shown
that B. garinii ST4 PBi is able to bind FHL-1 on its membrane.
van Burgel et al. BMC Microbiology 2010, 10:43
http://www.biomedcentral.com/1471-2180/10/43
Page 4 of 12Mapping of the binding domains of CFH and FHL-1 to
CspA orthologs
In order to map the binding regions of CFH and FHL-1
interacting with BGA66 and BGA71, various deletion con-
structs of CFH and FHL-1 were used for ligand affinity
assays (Fig 7). BGA66 bound to full-length CFH and FHL-
1, but to none of the deletion constructs lacking SCRs 5-7.
BGA71 bound FHL-1 as well as deletion constructs SCR1-
5 and SCR1-6. Thus, SCR5-7 of both CFH and FHL-1 are
required for binding to BGA66 and BGA71.
Expression of BGA66 and BGA71 by real-time RT-PCR
cDNA prepared from in vitro cultured B. garinii ST4
PBi were tested in a quantitative real time PCR. Cultures
repeated in sexplet demonstrated a mean expression of
B G A 6 6o f3 4c o p i e s / 1 0 0 0c o p i e sflaB (SD 22) and
B G A 7 12 1c o p i e s / 1 0 0 0c o p i e sflaB ( S D1 8 ) .A l ls p i r o -
chetes cultivated in vitro expressed BGA66 and BGA71
simultaneously.
Analysis of CFH binding of different animal sera to CspA
orthologs
A variety of sera obtained from different animals were
used to analyse binding of CFH to CspA, BGA66,
BGA67, BGA68, and BGA71 by ligand affinity blotting.
A ss h o w ni nF i g8 ,C s p Ao r t h ologs displayed distinct
capacity of binding to CFH from a wide variety of sera
from different mammals and poultry. All orthologs exhi-
bit binding of CFH from bovine, equine and canine
serum with different intensities. BGA68 and BGA71
showed a weak binding capacity to murine CFH. In
addition, BGA68 but not CspA nor other orthologs
bound to avian CFH. Porcine and feline serum proteins
did not bind any of the CspA orthologs of B. garinii
ST4 PBi while feline CFH appears to bind only to
BbCspA.
Discussion
We are the first to demonstrate that B. garinii ST4 PBi
is serum resistant and is able to acquire FHL-1 but not
CFH from human serum. In addition, we identified two
distinct CspA orthologs, BGA66 and BGA71 as potential
ligands of complement regulators CFH and FHL-1.
These proteins were produced under in vitro conditions
as demonstrated by real time PCR. Finally, we demon-
strated distinct binding capacities of CFH of different
mammalian and avian origin to different CspA orthologs
of serum resistant B. garinii ST4 PBi.
In Europe four human pathogenic genospecies are
endemic. B. burgdorferi ss, B. afzelii,a n dB. spielmanii
display a human serum resistant phenotype while B.
Figure 5 Binding capabilities of CFH and FHL-1 to CspA orthologs of B. garinii ST4. Purified GST fusion proteins, BbCspA, BGA66, BGA67,
BGA69, and BGA71 (500 ng/lane) were subjected to 10% Tris/Tricine SDS-PAGE and blotted to nitrocellulose membranes. Membranes were then
incubated with recombinant FHL-1 or with NHS. GST-fusion proteins were detected by using anti-goat GST antibody and binding to CFH and
FHL-1 were visualized using mAb VIG8 specific for the C-terminal region of CFH and aSCR1-4 antiserum specific for the N-terminal region of
FHL-1. Binding of CFH and FHL-1 is visible for BGA66 and BGA71.
Figure 4 Accessibility of CFH/FHL-1 binding proteins of B.
garinii ST4 PBi by different proteases. Spirochetes of B. garinii
ST4 PBi were incubated with either proteinase K or trypsin at
concentrations of 12.5 to 100 μg/ml or in buffer without any
protease (0). After 1 h of incubation, cells were lysed by sonication
as described in Materials and Methods. Each protein lysate was then
subjected to 10% Tris/Tricine SDS-PAGE, blotted to membranes, and
analyzed by Western or ligand affinity blotting. CFH/FHL-1 binding
proteins were identified using NHS and a polyclonal anti-CFH
antibody. Equal sample loading was assessed by detection of
flagellin (FlaB) using MAb L41 1C11 1C11 at a dilution of 1:1000.
Mobilities of molecular mass standards are indicated to the left.
Four proteins able to bind CFH/FHL-1 and they are readily digested
by proteinases and therefore located on the membrane.
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Within the OspA typing scheme, B. garinii ST4 strains
represent a distinct branch as shown by random ampli-
fied polymorphic DNA (RAPD) analysis. On the basis of
MLSA analysis it has recently been proposed, though
not yet generally accepted, to delineate this subgroup in
a separate species; B. bavariensis [7,40]. B. garinii ST4 is
remarkably often associated with dissemination to the
CNS [3,5,6,41]. In a previous study it was confirmed
that B. garinii non-ST4 strains, including strains isolated
from CSF, are sensitive to complement while B. garinii
ST4 strains were resistant to human complement [10].
In this report we confirm with an in vitro killing assay
and IF that B. garinii ST4 is resistant to human comple-
ment killing and that it does not allow formation of
MAC on the spirochetal membrane.
It has been extensively shown that CspA fulfils a key
role in complement resistance of B. burgdorferi ss
[42,43]. In the present study, a comparative binding ana-
lysis was conducted to isolate and characterize CspA
Figure 6 Binding of CspA orthologs to FHL-1 and CFH. Recombinant proteins (500 ng each) were coated onto an ELISA plate and incubated
with purified FHL-1 (A) and CFH (B). Binding was assayed by ELISA using polyclonal aSCR1-4 that recognized CFH and FHL-1. All experiments
were performed at least in triplicate. * (p < 0.05 compared to baseline (GST) OD)
Figure 7 Mapping of the binding domains of CFH and FHL-1 for BGA66 and BGA71. Schematic representation of the CFH and FHL-1
protein and ligand affininty blot analysis of fusion proteins. The complement regulatory domains SCR 1-4 are in checked. Purified recombinant
protein was separated by 10% Tris-Tricine-SDS-PAGE and transferred to nitrocellulose. Membranes were incubated with either recombinant FHL-1
(FH1-7) or several deletion constructs of CFH (FH1-2, FH1-3, FH1-4, FH1-5, FH1-6, FH8-20) or with human serum (FH). Bound proteins were
visualized using polyclonal goat anti-CFH (Calbiochem), or MAb VIG8 directed against the C-terminus of CFH. SCR 5-7 are essential SCR for
binding of BGA66 and BGA71 to interact with CFH/FHL-1.
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PBi. We hypothesised that binding of CFH and/or FHL-
1 via CspA orthologs contributes to serum resistance of
B. garinii ST4 PBi. We identified orthologs BGA66 and
BGA71 but not BGA67 and BGA68 as being potential
ligands for FHL-1 and CFH. In vitro cultured spiro-
chetes bound FHL-1 but not CFH on their surface. The
affinity for FHL-1 appeared to be stronger than for
CFH, it can be concluded that FHL-1 competes with
CFH for the same binding site and thus CFH could not
be detected in the cell binding assay. When employing
ELISA on recombinant proteins, BGA66 bound both
complement regulators while BGA71 only bound FHL-
1. By ligand affinity blotting BGA71 bound FHL-1 as
well as CFH. A logical explanation for this phenomenon
might be the denaturing conditions of the Western blot,
suggesting that native BGA71 specifically interacts with
FHL-1 only.
Furthermore, it was previously shown that CspA
forms homodimers and three regions of CspA have
been implicated in formation of a functional binding site
of CspA to CFH/FHL-1 [35-37,43]. Previously it has
been hypothesised that the C-terminal YKXXDXXXP
motif is important in binding of CFH and FHL-1, as
well as the lysine residue at position 246 of CspA [31].
Recently it was also shown that a leucine residue at
position 146 within the proposed CFH binding region 1
as well as Tyr240, Asp242 and Leu246 within the pro-
posed binding region 3 of CspA were important in bind-
ing of CFH and FHL-1 [35]. The C-terminus of all
known human CFH/FHL-1 binding CspA and the B.
garinii ST4 gbb54 orthologs is shown in table 1. Com-
parative sequence analysis revealed that the C-terminus
of BGA66 and BGA71 are highly homologous to the C-
terminus of all known human CFH/FHL-1 binding
CspA. Ortholog BGA66 contains the C-terminal motif
as well as the Leu246, while BGA71 contains the C-
terminal motif but has a phenylalanine instead of a leu-
cine residue at position 246. Positions 146 and 240 are
unchanged in BGA66 and BGA71 both orthologs show
substitutions at position 242; the Asp242 in BGA66 and
BGA71 is replaced by a glutamic acid and a threonine
residue, respectively. A substitution of Asp242 by a neu-
tral alanine residue within CspA did not have a signifi-
cant effect on binding, while the replacement of aspartic
acid by tyrosine at this position influenced binding of
FHL-1 and is associated with a loss of binding of CFH
[35]. Lack of binding of native BGA71 to CFH is likely
to be due to the non-synonymous mutation of aspartic
acid by threonine, while BGA66 can still bind both CFH
and FHL-1 due to the synonymous mutation of aspartic
acid to glutamic acid. It is likely that absence of CFH
binding by BGA71 might be a result of an effect of the
mutation on protein folding and conformation. Our
finding that under denaturing conditions BGA71 can
bind CFH, but not under native folded conditions sup-
ports this hypothesis.
A number of Gram-negative as well as Gram-positive
bacteria have already been shown to be able to bind
CFH in order to protect themselves from complement-
mediated lysis [44-46]. CFH possess three binding sites
for complement C3b, however the only essential binding
site is SCR1-4 [12,47,48]. Here we show that BGA66 as
well as BGA71 bind SCR5-7 of CFH and FHL-1, thus
leaving the N-terminus free for maintaining their regula-
tory activity in factor I-mediated inactivation of C3b
[34]. Our finding indicates that B. garinii ST4 strains
can bind functionally active CFH and FHL-1 on the
membrane by BGA66 and BGA71 in order to evade
complement activation.
B. burgdorferi sl has developed an intriguing system to
respond to changes of the microenvironments by coor-
dinated expression of proteins. In vitro experiments
usually do not completely mirror the expression patterns
of CspA during the tick to mammal infectious cycle and
might also vary in cultured population [49]. CspA shows
ad i s t i n c te x p r e s s i o np r o f i l ea si ti sm a i n l ye x p r e s s e d
during transmission of spirochetes from the tick-to-
mammal and mammal-to-tick infection cycle [19]. Pre-
viously antibodies to CspA could be detected in sera
from infected mice and from Lyme disease patients sug-
gesting prolonged expression of CspA in the mamma-
lian host [50-52]. In the present study we demonstrated
that in vitro B. garinii ST4 PBi is capable of expressing
BGA66 and BGA71. Experiments regarding expression
of BGA66 and BGA71 during tick-to-mammal transmis-
sion and mammalian infection are ongoing and will give
more insight in their function in vivo.
Although all five CRASPs of B. burgdorferi sl are pri-
marily identified as ligands of human complement regu-
lators, several studies clearly showed that CspA can also
bind CFH from other mammalian hosts [22]. CFH bind-
ing of several animal CFH sources has also been
reported in a recent article where new CFH binding
proteins were identified [53]. It is still not quite clear
how the wide variety of complement resistance is
obtained in strains that do not interact with human
CFH. The B. burgdorferi ss and B. afzelii orthologs of
CspA were previously not studied for binding to CFH of
non-human origin. In this study all CspA orthologs of
B. garinii ST4 PBi were tested with whole sera from dif-
ferent animals. BGA67 and BGA68 lack binding to
human CFH but were able to interact with CFH from
other hosts, of which some are not competent reservoir
hosts for Borrelia.I ti sl i k e l yt h a ts e v e r a lm e m b e r so f
the gbb54 paralogous family are designated to bind CFH
from other species in the infectious cycle and are there-
fore not redundant but essential for infection of a wide
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CspA orthologs of B. burgdorferi sl might unveil a part
of the serum resistance patterns obtained from in vitro
experiments.
Conclusions
In this study we demonstrated B. garinii ST4 PBi is able
to evade complement killing and it can bind FHL-1 to
membrane expressed proteins. Recombinant proteins
BGA66 can bind FHL-1 and human CFH, while BGA71
can bind only FHL-1. All recombinant CspA orthologs
from PBi can bind CFH from different animal origins.
This can partly explain the wide variety of animals that
B. garinii can infect.
Methods
Borrelial strains and culture conditions
B. garinii strains PBi and VSBP as well as B. burgdorferi
ss strain B31 were cultured until mid-log phase (5 × 10
7
cells per ml) at 33°C in modified Barbour-Stoenner-
Kelly (BSK-H) medium (Sigma). Aliquots of 1 ml were
then diluted 1:1 with glycerol peptone (8% glycerol, 1%
w/v Proteose Peptone 3 (Brunschwig chemie, Amster-
dam) in distilled water), dispensed into screw-cap tubes
(Nunc, Wiesbaden, Germany), frozen at -80°C, and used
as stock cultures. Prior to use, a frozen suspension of
spirochetes was thawed and inoculated into fresh BSK-
H medium.
Serum bactericidal assay
Serum susceptibility of Borrelia was determined as
described previously [10]. Briefly, serum obtained from a
non-immune human donor (NHS) was frozen at -80°C
and thawed on ice prior to use. Heat inactivated (HI)
serum was incubated for 1 hour at 56°C in order to
inactivate complement. B. garinii ST4 PBi, B. garinii
non-ST4 VSBP, and B. burgdorferi ss B31 were cultured
until mid-log phase in BSK-H. An aliquot of 50 μlc o n -
taining 10
7 live Borrelia/ml was added to 50 μl of serum
and incubated for 1 and 3 h at 33°C. After incubation
aliquots of 5 μlw e r ed r a w nf r o mt h es u s p e n s i o n sa n d
mobility and blebbing of the spirochetes was assessed
under dark-field microscopy. One hundred spirochetes
were examined, motile cells as well as non-motile cells
were counted and the percentage of survival was calcu-
lated. The experiment was repeated three times.
Immunofluorescence assay
Immunofluorescence microscopy was performed as
described previously [54].
Briefly, freshly cultured B. garinii strains PBi, VSBP,
and B. burgdorferi ss B31 were incubated for 30 minutes
in BSK-H medium containing 25% NHS. Subsequently
spirochetes were washed twice with PBS/1% BSA, resus-
pended in the same buffer and air dried on microscope
slides overnight. After fixation in 100% methanol, slides
were incubated with human immune serum containing
anti-Borrelia antibodies (1:2000) and a mAb recognizing
a neoepitope of the terminal C5b-9 complex (1:1000)
(DAKO). Slides were washed with PBS-1% BSA and
incubated with an anti-human immunoglobulin G-fluor-
escein isothiocyanate-labeled antibody (1:100) (bioMér-
ieux) and an anti-mouse immunoglobulin G Cy3-labeled
antibody (1:1000) (Jackson). Afterwards slides were
washed three times and mounted with Mowiol
(Hoechst). Spirochetes were visualized by confocal
Figure 8 Interaction of different CspA orthologs to interact
with animal CFH. Purified recombinant CspA and B. garinii ST4
CspA orthologs were subjected to 10% Tris/Tricine SDS-PAGE and
blotted to nitrocellulose membranes. Recombinant proteins were
visualized by an anti-GST antibody. Additional membranes were
incubated with sera obtained from diverse animals. Interacting
proteins were then visualized using a polyclonal anti-CFH antibody.
Table 1 C-terminus of all CspA and B. garinii ST4 CspA
orthologs
Protein 240 250
BbCspA Y YKD F D T L KPAFY
BaCspA N YKD L D S F NPI N-
BgCspAa N YKE F D P L NLDY-
BgCspAb N YKT L D S F KSI N-
BGA66 N YKE H D S L KPI Y-
BGA67 N YKE FNSL KPI Y-
BGA68 N YKN LHSF KTVYY
BGA71 N YKT L D S F KPI N-
C-terminal end of CspA orthologs described in this study and previously
determined. Positions 242 and 246 depicted in italic. The sequence for CspA
derived from B. burgdorferi ss B31, BaCspA from B. afzelii MMS, ZQA68
(BgCspAa) and ZQA71 (BgCspA b) from B. garinii ZQ1, BGA66, BGA67, BGA68
and BGA71 from B. garinii ST4 PBi.
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microscope (Carl Zeiss).
Serum adsorption experiments
Borrelia (2 × 10
9 cells) were grown to mid-log phase,
harvested by centrifugation (5,000 × g, 30 min, 4°C), and
resuspended in 100 μl of veronal-buffered saline (sup-
plemented with 1 mM Mg
2+-0.15 mM Ca
2+-0.1% gela-
tine, pH 7.4). To inhibit complement activation, NHS
was incubated with 0.34 mM EDTA for 15 min at room
temperature. The spirochete suspension was then incu-
bated in 1.5 ml of NHS-EDTA for 1 hour at room tem-
perature with gentle agitation. After three washes with
phosphate-buffered saline (PBS) (supplemented with.15
M NaCl, 0.03 M phosphate, 0.02% sodium azide, pH
7.2), 0.05% Tween 20. The proteins bound to the cells
were eluted by incubation with 0.1 M glycine-HCl, pH
2.0, for 15 min. Cells were removed by centrifugation at
14,000 × g for 20 min at 4°C, and supernatants were
then analysed by Western blotting.
Protease degradation assay
To characterize protease-susceptibility of CFH and FHL-
1 binding proteins of B. garinii ST4 PBi, cells were trea-
ted with two different proteases as described previously
[34]. Briefly, spirochetes were grown to mid-log phase,
sedimented by centrifugation at 5,000 × g for 30 min,
washed twice with cold PBS containing 5 mM MgCl2
(PBS-Mg), and resuspended in 100 μlP B S - M g .T ot h e
Borrelia cell suspension (at a concentration of 10
8 in a
final volume of 0.5 ml), proteinase K or trypsin was
added to a final concentration of 12,5 μg/ml to 100 μg/
ml. Following incubation for 1 hour at room
temperature, proteolytic degradation with proteinase K
or trypsin was terminated by the addition of 5 μl of phe-
nylmethylsulfonyl fluoride or by the addition of 5 μlo f
phenylmethylsulfonyl fluoride and 5 μlo f4 - ( 2 - a m i -
noethyl)-benzenesulfonyl fluoride, respectively. Borrelia
were then gently washed twice with PBS-Mg, resus-
pended in 20 μl PBS-Mg, and lysed by sonication five
times using a Branson B-12 sonifier (Heinemann,
Schwäbisch Gmünd, Germany). Equal volumes of Borre-
lia lysates were subjected to Tris/Tricine SDS-PAGE,
and proteins were transferred to nitrocellulose mem-
branes as described previously [16]. Susceptibility of
proteins to proteolytic degradation was assessed by
Western or ligand affinity blotting with the appropriate
monoclonal or polyclonal antibodies, followed by incu-
bation with a horseradish peroxidase-conjugated IgG
antibody, and then visualized by the addition of 3, 3’,5 ,
5’-tetramethylbenzidine.
PCR cloning, expression and purification of recombinant
CspA orthologous proteins
Sequences of genes encoding for CspA B31 and orthologs
from B. garinii ST4 PBi were obtained from genbank
(NC_006129 and NC_001857). Primers were designed
using primer3 (MIT) and listed in table 2. Amplification
reactions were performed in a 50 μl final volume, contain-
ing 25 μl IQ Supermix (Bio-Rad, Veenendaal, The Nether-
lands), 15 pmol forward primer, 15 pmol reverse primer,
and 10 μl of a DNA isolate of cultured B31 or PBi. Follow-
ing an enzyme activation step for 3 min at 95°C, amplifica-
tion comprised 50 cycles of 30 s at 95°C, 30 s at 55°C and
30 s at 72°C. Genes lacking their leader sequences were
ligated in frame into the pGEX-5X3 vector (Amersham
Table 2 Oligonucleotides used in this study
Oligonucleotides Sequence (5’-3’) Target
BBA68s ATGCGGCCGTGTTGTGTTTTAGTTTGGAT BBA68
BBA68as GTGGGATCCCATGCGCACCTTTTAGCAA BBA68
BGA66s ATGCGGCCGTGTTTTTAGTTTGGGCTCT BGA66
BGA66as GTGGGATCCCATGTGCCGTTAATAAAAATTG BGA66
BGA67s ATGCGGCCGATCAAGTGCAACGTATTTTT BGA67
BGA67as GTGGGATCCCATGTGCCGTTAATAAAAATTG BGA67
BGA68s ATGCGGCCGACATTATTGTTTTTAGTTTGGACTCT BGA68
BGA68as GTGGGATCCCATGTGCTGATAAAACC BGA68
BGA71s ATGCGGCCCATTGTTGTTTTTGGTTTAGACTC BGA71
BGA71as GTGGGATCCCATGTGTGCTGTTGATAAAATAG BGA71
qFlaBs GCTTCTGATGATGCTGCTG FlaB
qFlaBas TCGTCTGTAAGTTGCTCTATTTC FlaB
qFlaB Taqmanprobe GAATTRGCAGTAACGG-FAM FlaB
qBGA66s AGTTGTGCAGCAGCAATTTT BGA66
qBGA66as ATCCAGATCCTTTAAAGAC BGA66
qBGA71s TTCATATAGGTTGCTAATGCG BGA71
qBGA71as TTGCACACTCAAAACCAAAAA BGA71
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were used to transform Escherichia coli MC1061. Plasmid
DNA was prepared from the presumptive clones with the
QIAprep kit (QIAGEN, Hilden, Germany), and the Borre-
lia DNA inserts were sequenced using the BigDye Termi-
nator cycle sequencing kit (Applied Biosystems
International, Foster City, CA, USA) in accordance with
the manufacturers’ recommendations. Plasmids were used
to transform E. coli BL21. Expression of the GST fusion
p r o t e i n sw a sd o n eb yi n d u c t i o no ft h er e s p e c t i v eB L 2 1
clones induced for 5 hours with 1 mM IPTG, followed by
affinity purification with glutathione-Sepharose 4B (GE
Healthcare, Netherlands). Expression and purity of gener-
ated GST fusion proteins were confirmed by employing
SDS-PAGE, and protein concentrations were determined
by a Bradford assay (Bio-Rad, Munich, Germany).
Real Time-PCR analysis
For determining expression in vitro cultures of PBi spir-
ochetes grown to mid log phase were isolated. Nucleic
acid was extracted with a QiaAmp Mini Blood DNA kit
(Qiagen, Hilden, Germany).
Total nucleic acid was treated with DNAse and 1 μg
RNA was reverse transcribed using iScript (Bio-Rad)
according to the manufacturer’s protocol. Primers and
probe for the flaB gene were designed from an interspe-
cies conserved region of flaB using the Beacondesigner
and listed in table 2. Amplification reactions were per-
formed in a 50-μl final volume, containing 25 μlI Q
Supermix (Bio-Rad, Veenendaal, The Netherlands), 15
pmol forward primer, 15 pmol reverse primer, 2.5 mM
MgCl2,0 . 3μM FlaB-probe, or 1 × Sybergreen (Molecu-
lar Probes), and 10 μl cDNA. Following an enzyme acti-
vation step for 3 min at 95°C, amplification comprised
50 cycles of 30 sec at 95°C, 30 s at 55°C and 30 s at 72°
C in an iCycler IQ real-time detection system (Bio-Rad).
The FlaB assay was optimized using a TA vector into
which the complete flaB encoding gene from B. burg-
dorferi ss B31 had been cloned and had an analytical
sensitivity of 1 copy per PCR in 0.9% saline.
Quantitative DNA analysis was performed using the
Icycler IQ5 PCR system.
The relative starting copy number was determined by
cycle threshold detection using Icycler relative quantifi-
cation software (Roche).
SDS-PAGE, ligand affinity blot analysis, and Western
blotting
Purified recombinant fusion proteins (500 ng) were
subjected to 10% Tris/Tricine-SDS-PAGE under redu-
cing conditions and transferred to nitrocellulose as
previously described [16,55]. Briefly, after transfer of
proteins onto nitrocellulose, nonspecific binding sides
were blocked using 5% (w/v) dried milk in TBS (50
mM Tris-HCl (pH 7.5), 200 mM NaCl,0.1% Tween 20
for 1 hour at room temperature. Subsequently, mem-
branes were rinsed four times in TBS and incubated
for 1 hour at room temperature with TBS containing
recombinant FHL-1, pooled non-immune human
s e r u m( N H S ) ,o rn o n - i m m u n ea n i m a ls e r a .T od e t e c t
the fusion proteins a goat anti-GST antibody (dilution
1:2,000) (GE Healthcare, Germany) was used. Polyclo-
nal rabbit anti-SCR1-4 antiserum (aSCR1-4) (dilution
1:1,000) used for the detection of FHL-1 and monoclo-
nal antibody (mAb) VIG8 (undiluted) against the C-
terminus of CFH, are described elsewhere [15,56].
A f t e rf o u rw a s h i n g sw i t h5 0m MT r i s - H C l( p H7 . 5 ) -
150 mM NaCl-0.2% Tween 20 (TBST), membranes
were incubated for 1 hour with either a polyclonal rab-
bit antiserum recognizing the N-terminal region of
CFH (aSCR1-4) or mAb VIG8, directed against the C-
terminus of CFH. Following four washes with TBST,
strips were incubated with a peroxidase-conjugated
anti-rabbit IgG antibody or with a peroxidase-conju-
gated anti-mouse IgG antibody (DAKO, Glostrup,
Denmark) for 1 hour at room temperature. Detection
of bound antibodies was performed by using 3, 3’,5 ,
5’-tetramethylbenzidine as substrate.
ELISA
Recombinant proteins (500 ng/well) were immobilized
on wells of a microtiter plate overnight at 4ºC. Unspe-
cific binding sites were blocked with 0.1% gelatin in
PBS for 6 h at 4ºC. CFH (Calbiochem), or recombinant
FHL-1 was added to the wells and left overnight at
4ºC. Polyclonal goat anti-CFH antibody (Calbiochem)
was added for 3 h at room temperature, protein com-
plexes were identified using secondary horseradish per-
oxidase-coupled antiserum. The reaction was
developed with 1,2-phenylenediamine dihydrochloride
(Dako-Cytomation), and absorbence was measured at
490 nm.
Binding domains of CFH and FHL-1 to CspA orthologs
To identify domains of CFH and FHL-1 responsible for
binding of BGA66 and BGA71, 500 ng purified recombi-
nant protein was separated by 10% Tris/Tricine SDS-
PAGE and transferred to nitrocellulose. Membranes
were then incubated with either recombinant FHL-1
(FH1-7), deletion constructs of CFH (FH1-2, FH1-3,
FH1-4, FH1-5, FH1-6, FH8-20, FH19-20), or human
serum as source for CFH. Bound proteins were visua-
lized using polyclonal goat anti-CFH antibody (Calbio-
chem), or mAb VIG8.
Statistical analysis
All statistical analyses were done using SPSS 16.0 and
Microsoft Excel software. The two-tailed Student t-test
van Burgel et al. BMC Microbiology 2010, 10:43
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were considered to be significant.
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